Prevan

Quick links to important sections

Prevan

Method of action: Antianemic

Treatment option: Iron Deficiency

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prevan

Property Description
Active Ingredient Iron Dextran
Form Injectable Solution (Sterile Liquid)
Pharmacological Class Iron Replacement Product, Hematinic
General Purpose Correcting Iron-Deficiency Anemia
Origin Synthetic Iron Carbohydrate Complex

What Type of Medicine is Prevan (Iron Dextran)?

Prevan is a Prescription-only pharmaceutical product classified as an Iron Replacement Product, falling within the broader group of Hematinics. Its primary purpose is to address significant Iron Deficiency and Iron-Deficiency Anemia. This medication is utilized in patients who are intolerant to or fail to respond adequately to standard oral iron administration for ensuring iron restoration. The drug is indicated for documented iron deficiency conditions when oral administration is unsatisfactory or impossible.

As a therapeutic intervention, it provides a means to directly restore the body's iron supply, which is necessary for the fundamental production of Hemoglobin and healthy red blood cells. Prevan, like its generic counterparts, is distinct in its method of delivery, requiring Parenteral Administration via injection, which bypasses common absorption challenges.


Composition and Form: The Iron Carbohydrate Complex

The sole Active Ingredient in Prevan is Iron Dextran, a synthetic compound structurally known as an Iron Carbohydrate Complex. This product is supplied as a Sterile Liquid formulated for injection, classifying it as an Injectable Solution. The Iron Dextran complex is chemically engineered from Ferric Hydroxide combined with Dextran, a polyglucose molecule that acts as a stabilizing carrier. Iron Dextran is a complex of ferric hydroxide and a hydrogenated dextran fraction. This colloidal suspension possesses a stable and controlled release profile suitable for direct administration.

This formulation permits its administration either through Intravenous (IV) Use or Intramuscular (IM) Use. The compound functions as a prodrug by carrying the iron safely into the body until the complex is processed naturally, ensuring a controlled and efficient delivery system.


The General Purpose of Parenteral Iron Therapy

The general function of Prevan is to provide the immediate and effective Replenishment of Iron Stores that are severely depleted. By delivering the Ferric Iron directly into the circulation, the drug bypasses potential barriers to absorption in the gut. This action provides the necessary raw material required for the body to synthesize crucial oxygen-carrying proteins.

Ultimately, by restoring the essential mineral iron, this specialized therapy aids in reversing the underlying pathology of Iron-Deficiency Anemia, leading to the fundamental restoration of the blood’s capacity to transport oxygen throughout the body and improving overall cellular function.

What side effects are possible with Prevan?

Possible Side Effects and Safety Information

The officially documented safety profile for Prevan (Iron Dextran) is structured by the categorization of adverse effects and specific regulatory constraints detailed in government prescribing information, such as the FDA and EMA SmPC. The most critical safety information documented is the risk of severe hypersensitivity reactions, including potentially fatal anaphylactic-type reactions. These reactions can occur immediately following administration, often involving respiratory difficulty or cardiovascular collapse.


Adverse reactions are classified according to the systems affected and include those listed as Common and those that are Delayed in onset.

  • System-Organ Classes Involved: Adverse effects are documented in the Vascular Disorders (e.g., hypotension), Cardiac Disorders, Gastrointestinal Disorders (e.g., nausea and vomiting), and Musculoskeletal and Connective Tissue Disorders (e.g., arthralgia and myalgia).
  • Time-Related Patterns: While severe reactions can be immediate, delayed reactions are frequently noted, typically appearing 24 to 48 hours after administration and including symptoms like fever, headache, and joint pain.

Regulatory Safety Constraints

The use of injectable Iron Dextran is subject to strict limitations. It is contraindicated in patients with a known hypersensitivity to the medicine and in those with anemias not caused by iron deficiency. Safety considerations also apply to specific populations, including patients with severe liver dysfunction or pre-existing cardiovascular disease, where extreme caution is advised.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Prevan

The regulatory profile for Iron Dextran overdose is defined by two primary risks: acute anaphylactic-type reactions and chronic iron overload known as iatrogenic hemosiderosis. Overdose may result in life-threatening and fatal outcomes due to severe reactions that include hypotension, circulatory failure, seizures, and cardiac arrest, as stated in regulatory documents.

Documented Overdose Manifestations

Manifestation Type Examples (Documented in Labeling)
Acute Reactions Severe hypotension, shock, cardiac arrest, respiratory difficulty.
Delayed Reactions Arthralgia (joint pain), fever, headache, malaise, vomiting.
Chronic Toxicity Iatrogenic hemosiderosis (excessive iron storage).

Emergency Actions and Monitoring

Official regulatory statements mandate that any signs or symptoms of an acute reaction or a suspected overdose require that immediate medical attention must be sought. The drug should only be administered in a setting where resuscitation equipment and personnel trained in treating anaphylactic-type reactions are readily available. This preparedness includes having Epinephrine immediately available. Furthermore, patients with a suspected overdose or those receiving extended therapy require periodic monitoring of hematologic and iron parameters to detect and manage the risk of chronic iron overload. The regulatory labeling notes that the risk of toxicity is increased in patients with serious impairment of liver function and that severe reactions in pregnant women may cause fetal bradycardia.

Therapeutic Uses of Prevan

Main Uses of Prevan

Prevan is a medication primarily indicated for the prevention of pneumococcal disease caused by specific strains of the bacterium Streptococcus pneumoniae. This bacterium is responsible for several types of infections, ranging from mild respiratory issues to severe, invasive conditions.

The medication is used to protect against various manifestations of pneumococcal infection, including:

  • Invasive Pneumococcal Disease: This includes serious infections such as bacteremia (bloodstream infection) and meningitis (inflammation of the membranes surrounding the brain and spinal cord).
  • Pneumonia: Prevan is utilized to reduce the risk of lung infections caused by the serotypes included in the formulation.
  • Acute Otitis Media: In pediatric populations, the medication is also indicated for the prevention of middle ear infections specifically caused by the targeted bacterial strains.

Clinical Benefits

The primary benefit of Prevan is the stimulation of the body's immune system to recognize and fight the most common or aggressive types of pneumococcal bacteria.

Reduction in Disease Burden

By providing protection against the specific serotypes contained within the medication, it helps decrease the overall incidence of community-acquired pneumonia and invasive bacterial infections. This is particularly significant for populations at higher risk, such as young children and older adults.

Long-term Immunological Memory

The medication works by inducing an immune response that creates "memory" cells. If the individual is exposed to these bacteria in the future, the immune system can respond more rapidly and effectively to prevent the infection from developing or becoming severe.

Community Protection

While the primary goal is individual protection, widespread use contributes to a reduction in the carriage of these bacteria within the population. This can lead to a secondary benefit where the transmission of the bacteria is lowered, indirectly protecting those who may not be able to develop a full immune response themselves.

Eligibility and Restrictions for Use

Who Can and Cannot Use Prevan: Official Eligibility Information

Official regulatory guidelines define specific patient populations allowed to use Prevan (Iron Dextran) and those for whom its use is strictly prohibited. The medicine is primarily intended for adults with documented Iron Deficiency Anemia (IDA) who have demonstrated an unsatisfactory response to, or intolerance of, standard oral iron supplements.


Contraindications and Restrictions

Classification Population or Condition
Contraindicated Patients with known hypersensitivity to Iron Dextran or any excipients.
Individuals with pre-existing iron overload (e.g., hemochromatosis).
Patients with anemias not due to iron deficiency.
Patients with an acute bacterial or viral infection or decompensated cirrhosis.
Conditional Use Patients with severe asthma or controlled hepatic impairment.

Age and Physiological Limitations

Safety and effectiveness have not been fully established in the overall pediatric population; use is generally not recommended in infants under four months of age. For pregnancy, use is considered conditional and only permitted when the documented benefit to the patient clearly outweighs potential risks. Use during lactation requires regulatory caution.

What should I know about interactions with other medicines?

Prevan, which contains the active substance bupropion, has a significant potential for drug-drug interactions, primarily due to its effects on drug-metabolizing enzymes. The most crucial interaction involves its powerful inhibition of the Cytochrome P450 2D6 (CYP2D6) enzyme. Co-administration with medicines primarily metabolized by CYP2D6 can lead to increased exposure and potential toxicity of the co-administered drug.

Major Contraindicated Combinations

Bupropion is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), including therapeutic agents like phenelzine or tranylcypromine, and substances such as linezolid or intravenous methylene blue. This combination must be avoided due to the risk of serious reactions, including hypertensive crisis or increased seizure risk. A washout period of at least 14 days is required when switching between bupropion and an MAOI.

Clinically Significant Interactions

Interactions that require dosage adjustment or careful monitoring are divided into two main categories:

  • CYP2D6 Substrates: Products metabolized by this enzyme (e.g., certain beta-blockers, antiarrhythmics, selective serotonin reuptake inhibitors, and antipsychotics) may require a reduced dose due to increased concentrations in the bloodstream when taken with bupropion.
  • Seizure Threshold-Lowering Agents: The concurrent use of bupropion with medicines that also lower the seizure threshold—such as certain antipsychotics, theophylline, and systemic corticosteroids—may increase the risk of seizures. Caution and careful dose titration are advised.

Additionally, drugs that induce the CYP2B6 enzyme, such as efavirenz or ritonavir, can significantly lower the concentration of bupropion, potentially reducing its effectiveness. Conversely, strong CYP2B6 inhibitors may increase bupropion exposure. Avoidance or limitation of alcohol use is also a critical interaction-related restriction, as it can increase the risk of neuropsychiatric adverse events and seizures.

Mechanism of Action

Enhancing Inhibitory Neurotransmission (GABAergic Modulation)

Prevan's primary action involves the GABA-A receptor complex, specifically targeting the alpha1 subunit-containing subtypes. The molecule functions as a positive allosteric modulator, binding to a site separate from the GABA binding pocket. This interaction increases the receptor's affinity for the inhibitory neurotransmitter GABA, resulting in a greater influx of chloride ions ( Cl^-) into the postsynaptic neuron. This heightened inhibitory current causes neuronal hyperpolarization and systemic CNS depression, which includes the physiological consequence of reduced arousal and generalized dampening of CNS activity.

Stabilizing Neuronal Membrane Excitability

Additionally, Prevan engages in the direct blockade of certain voltage-gated sodium ( Nav) and T-type calcium ( Cav 3) channels. By limiting the rapid flow of these ions across the membrane, Prevan stabilizes the neuron's electrical resting state. This action specifically limits the cell's generation of high-frequency action potentials and works in conjunction with the GABAergic effect, contributing to reduced neuronal excitability across the central nervous system.

Dosage and Administration Information

How to Use Prevan — Official Administration Guidelines

Note: Specific, authorized administration instructions for a product named Prevan are not uniformly available across major official databases. The information below is structured based on a generalized model of mandates for use, which are typically located in the drug's official documentation or product insert.

Administration Scope

Category Official Regulatory Standard
Route of Administration [Specific route, e.g., Oral Tablet, Intravenous Infusion]
Dosing Schedule [Explicit dose in mg/kg or mg, and the maximum daily dose]
Frequency and Timing [Must be administered X times a day (e.g., every 12 hours)]
Preparation Requirements [e.g., Must be diluted in 100 mL of D5W; Do not shake vial]
Age-Group Rules [Separate dosing for pediatric patients (e.g., 2-12 years) or geriatric patients]
Missed-Dose Rules [Instruction to take the missed dose if within X hours, or to skip it]

Official Use Protocol

The precise procedural steps for administering any regulated medication must be followed exactly as documented by the authorizing health body. These steps ensure the drug is delivered correctly and safely, preventing deviations that could impact efficacy or patient safety. For all regulated therapies, the official use protocol typically involves a sequence of explicit steps:

  1. Preparation Check: Confirm the correct formulation, verify the dose based on prescription and patient factors (e.g., weight, renal function), and complete all stated preparation steps (e.g., reconstitution, dilution).
  2. Administration: Execute the administration process (e.g., swallowing the tablet whole, starting the X-minute infusion) according to the specified route and timing constraints.
  3. Post-Dose Action: Follow any stated post-administration procedures, such as monitoring the patient or noting the timing of the next scheduled dose.

Connection to the overall use protocol: The official protocol establishes a non-negotiable sequence for drug administration. It serves as the authoritative guide for healthcare professionals and patients, detailing every required action from product preparation through the timing of the subsequent dose, strictly excluding therapeutic or safety rationale.

Recent Clinical Evidence

Prevan: Recent Clinical Evidence

Evidence for Use in Iron-Deficiency Anemia (IDA)

The core evidence describing the clinical evaluation of Prevan was studied for adults and children with documented Iron-Deficiency Anemia (IDA) who either did not respond adequately to or could not tolerate standard oral iron supplements. Researchers explored the use of Prevan in Randomized Controlled Trials (RCTs) and various other studies, which were designed to measure changes in key markers such as Hemoglobin (Hb) and iron storage markers like Serum Ferritin and Transferrin Saturation (TSAT).

Findings describe patterns where measurements of key iron parameters were observed to change in the study populations during the defined time intervals of the study. This evidence contributes to the broader evidence landscape for iron replacement when the oral route is not a viable option. However, many pivotal studies describing this established treatment are older trials. While there is evidence on short-term iron status change, limited information is available for long-term outcomes and the durability of the change in iron markers is not fully established across all clinical settings.


Evidence for Patients with Absorption Challenges and CKD

Research has explored the use of Prevan in patient groups facing unique challenges, such as those with conditions that interfere with the gut’s ability to absorb iron, including individuals with Inflammatory Bowel Disease (IBD) or those who have had certain gastric surgeries. Studies monitored parenteral administration as a delivery route evaluated in research contexts involving compromised intestinal absorption. Findings describe group patterns where changes in iron status markers were observed in these cohorts.

The role of Prevan was also evaluated in patients with Non-Dialysis Dependent Chronic Kidney Disease (ND-CKD). Research describes measurements of changes in iron status markers and associated changes in Hemoglobin within the observed ND-CKD populations. However, comparative evidence is often lacking in direct head-to-head comparisons with placebo, and data for certain subgroups remain insufficient.


Research in Special Populations and Evidence Gaps

Prevan was studied for use in pregnant women who had a poor response to or severe intolerance of oral iron, typically during the second or third trimester. Studies monitored changes in Maternal Hemoglobin and Ferritin levels, and findings indicated that changes in maternal iron status were observed. The results apply only to the specific populations studied, and evidence providing definitive conclusions on fetal or long-term maternal clinical outcomes beyond iron marker correction is limited.

The overall research highlights that evidence quality varies across studies, and many key limitations exist, such as follow-up durations were short in many trials designed to show acute changes.

Key Studies & References National Institute for Health and Care Excellence (NICE) Guideline: Iron deficiency anaemia

Frequently Asked Questions (FAQ)

Common questions about Prevan (FAQ)

Q: What is the main reason Prevan is prescribed?

A: According to official regulatory documents, Prevan is approved and prescribed for the treatment of [Specific Condition X]. This is the sole indication defined in the official product information.


Q: Is Prevan a common type of medicine for [condition treated]?

A: Based on its official mechanism, Prevan is classified as a [GABAergic modulator/Neuronal stabilizer]. This classification places it within the general group of medicines officially designated for the management of [Condition Treated].


Q: How quickly does Prevan usually start to work?

A: The Clinical Pharmacology section of the official documents details how quickly Prevan is absorbed into the bloodstream. While a specific time for the patient to feel the effects is not always explicit, the available regulatory data indicates the drug is absorbed into the bloodstream quickly after administration.


Q: Do I have to take Prevan forever, or is it a short course?

A: Official regulatory documents define the intended duration of use based on the approved indication, describing it either for short-term use or for ongoing management. This is based on the condition being treated.


Q: What is the difference between Prevan and [similar drug]? (in terms of purpose)

A: The approved purpose of Prevan is defined by its official regulatory indication. Any differences in function from other medications can be factually determined by comparing the specific indications listed on each drug’s official governmental label.


Q: Can Prevan be taken with common pain relievers like ibuprofen?

A: The official drug interaction section of the label indicates whether known interactions exist with common drug classes such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include ibuprofen. The label specifically describes classes of substances that have documented interactions with Prevan.


Q: Is it okay to drink coffee while taking Prevan?

A: Official documents address interactions with substances that affect the central nervous system (CNS), particularly stimulants, as Prevan works as a CNS depressant. This information is detailed in the drug interaction section of the label.


Q: Are there any specific foods to avoid when using Prevan?

A: Official administration instructions specify if any food or specific type of food (like certain fruit juices) should be avoided because it can interfere with how Prevan is absorbed or processed by the body. This guidance is detailed in the product label.


Q: What are the most commonly reported side effects of Prevan?

A: Official regulatory documents, based on clinical trial data, list the most frequent adverse reactions. Commonly reported effects often include symptoms such as dizziness, drowsiness, and headache.


Q: Do the side effects of Prevan go away over time?

A: Official documentation details the observed duration of adverse events in clinical trials, noting whether effects were generally transient (temporary) and tended to lessen after the initial period of treatment with Prevan.


Q: Does Prevan cause weight changes?

A: Weight changes (either weight gain or weight loss) are reported as potential adverse reactions in the official regulatory documents if they were observed during the pre-approval clinical trials or post-market surveillance data for Prevan.


Q: Is Prevan known to affect sleep patterns?

A: Official regulatory adverse reaction data reports any known effects on sleep. This may include changes like somnolence (drowsiness), insomnia, or other sleep-related disturbances, which are categorized by how frequently they occurred in studies.


Q: Can Prevan be safely used by older adults (e.g., people over 65)?

A: Official documents include specific information regarding use in geriatric patients (typically those over 65). This information often notes that older individuals may have increased sensitivity to the medicine's effects and may need a modified starting dosage.


Q: Are there any warnings about using Prevan during pregnancy or breastfeeding?

A: The official label contains a Risk Summary for both pregnancy and breastfeeding. This summary details potential risks to the fetus or newborn and confirms whether the drug's components are known to pass into human milk.


Q: What is the typical timeframe for seeing the full effect of Prevan?

A: Clinical trial summaries found in the official documents detail the point in time when the medication showed its maximal treatment effect. This data provides the expectation for when the full effects of Prevan are typically observed.


Q: What happens if I miss a dose of Prevan?

A: Official guidelines typically provide instructions for a missed dose, clarifying whether it should be taken as soon as it is remembered or skipped if close to the next scheduled dose. This information is detailed in the official Administration section.


Q: Does Prevan interact with common supplements like multivitamins?

A: The official drug interaction section lists substances known to interact with Prevan. This includes specific vitamin compounds, minerals, or herbal supplements that may affect how the medicine is metabolized (processed by the body).


Q: Can I take Prevan if I have kidney issues?

A: The label provides specific information regarding use in patients with varying degrees of renal impairment (kidney issues). This section describes whether dose adjustment is needed or if the drug is contraindicated (not allowed) in cases of severe impairment.


Q: Does Prevan require any special monitoring or blood tests?

A: The official Warnings and Precautions section or the Dosing section states if specific laboratory monitoring, such as blood tests or liver function tests, is required or recommended to safely monitor treatment with Prevan.


Q: Is it normal to feel a little dizzy when first starting Prevan?

A: This effect has been observed frequently in clinical trials, particularly during the initial period of therapy or following a dosage adjustment. Official adverse reaction data reports dizziness as a common side effect.


Q: Is Prevan available as a generic medicine?

A: The official regulatory status determines the availability of a generic version of the medicine. The generic name of the active substance is listed on the regulatory label for Prevan.


Q: What are the risks if Prevan is taken with alcohol?

A: The label warns that combining Prevan with alcohol may increase the risk of serious adverse effects. Because Prevan is a CNS depressant, this combination may increase sedation, dizziness, and the risk of respiratory depression.


Q: Does Prevan interact with birth control pills?

A: The official drug interaction section of the label explicitly describes whether Prevan is known to affect the efficacy of hormonal contraceptives (birth control pills) or if the contraceptives affect the processing of Prevan.


Q: Can teenagers or children use Prevan?

A: Regulatory documents explicitly state the approved pediatric age groups (e.g., children 6 years and older) for which the safety and effectiveness of Prevan have been established. If not approved for a certain age group, the label will state that it has not been studied.


Q: What is the typical duration of treatment with Prevan?

A: The duration of treatment is clearly defined in the official indication for which the drug is approved. The regulatory documents state if Prevan is intended for short-term use (e.g., a few weeks) or for chronic, long-term management.


Q: Can Prevan make certain pre-existing conditions worse?

A: The official Contraindications and Warnings sections list specific pre-existing health conditions. These sections define which conditions (e.g., severe liver impairment, glaucoma) strictly prohibit the use of Prevan or require special caution and monitoring.


Q: What if I forget if I took my Prevan dose?

A: Official dosing guidelines provide instructions for how to proceed if a dose is forgotten, clarifying whether the dose should be taken or skipped entirely, based on the approved timing rules.


Q: Can I take Prevan if I have a history of heart problems?

A: The official label explicitly lists any cardiac (heart) conditions that may represent a contraindication or require close monitoring. The regulatory documents describe which heart problems could pose a risk when taking Prevan.


Q: Do any official documents describe the long-term effects of Prevan?

A: The Clinical Studies sections of the official documents include data collected over the full duration of clinical trials, which may span 6 months or longer. The safety and efficacy data collected over these timeframes describe the known long-term effects of Prevan.


Q: Is it necessary to take Prevan with food?

A: The official administration instructions clearly specify if Prevan should be taken with food, without food, or if the timing relative to meals has no impact on its absorption or processing in the body. This instruction is detailed in the Dosing section.


Q: Is Prevan safe to take with common cold or flu medicines?

A: The official interaction section provides guidance regarding co-administration with other medications that cause sedation, which are often found in cold and flu remedies. Prevan may increase the depressant effects of such medicines.


Q: What is the risk of a serious allergic reaction to Prevan?

A: The official Warnings and Precautions section includes information on hypersensitivity and the potential for rare but serious adverse reactions, such as anaphylaxis. This section lists the symptoms that should prompt immediate medical attention.


Q: Does Prevan interfere with laboratory test results?

A: The label includes a specific section that details any known interference that Prevan may cause with common laboratory or diagnostic test results, ensuring accurate interpretation of medical screenings.


Q: Can Prevan be used alongside herbal remedies?

A: The interaction data explicitly names any herbal products (e.g., St. John's Wort) known to affect the processing of Prevan in the body. This information defines whether co-use is forbidden or requires special caution.


Q: What is the proper way to stop taking Prevan?

A: Official regulatory documents state that discontinuation of this type of medicine typically involves gradually reducing the dosage over a specific period to help minimize the potential for withdrawal-type reactions.


Q: Is there a maximum dose of Prevan that is documented in official guidelines?

A: The Dosing and Administration section of the official label includes the specific maximum daily dose that has been authorized by the regulatory body. This dose should not be exceeded.


Q: Can men and women use Prevan the same way?

A: The dosing instructions provided in the official label generally apply to both men and women. The label specifies differences only if there are known variations based on sex that affect dosing or safety.


Q: Is Prevan known to cause mood changes?

A: The Adverse Reactions section reports any psychiatric disorders or mood-related changes. Official documentation describes mood changes (e.g., depression, agitation) that were observed during the clinical trial period for Prevan.


Q: Where can I find the official patient information leaflet for Prevan?

A: The most current official Patient Information Leaflet (PIL) or Medication Guide is publicly accessible through the governmental drug databases, such as DailyMed (FDA) or the European Medicines Agency (EMA) website.


Q: Does Prevan affect fertility?

A: The section detailing use in reproductive potential contains data from clinical or animal studies that describes any potential temporary or permanent effects of Prevan on fertility in both males and females.


Q: Are there different forms of Prevan (e.g., tablet, liquid)?

A: Official regulatory documents, specifically the Dosage Forms and Strengths section, explicitly list the specific presentations that have received regulatory approval (e.g., oral tablet, oral suspension, or injectable solution).

How should Prevan be stored and disposed of?

How to Store and Dispose of Prevan (Iron Dextran Injection)

Official regulatory documents define specific conditions for storing and disposing of Prevan to ensure its stability and safety. The sterile injection solution must be stored at controlled room temperature, typically below 25 C (77 F), and must be strictly protected from freezing. The container must be kept in its original package to protect from light.

Stability and Child Safety

Condition Requirement
Freezing Do not freeze
Diluted Solution Stability Stable for 24 hours at 25 C
Container Integrity Use only clear solutions without particles

All medicine must be stored out of the reach of children. Unused or expired Prevan must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prevan found in:

A-Z Index: